Navidea Biopharmaceuticals to Host First Quarter 2021 Earnings Conference Call and Corporate Update
May 04 2021 - 7:30AM
Business Wire
Conference Call to be Held on Tuesday, May 11,
2021 at 5:00 p.m. (EDT)
Navidea Biopharmaceuticals, Inc. (NYSE
American: NAVB) (“Navidea” or the “Company”), a company focused on
the development of precision immunodiagnostic agents and
immunotherapeutics, today announced it will host a conference call
and webcast on Tuesday, May 11 2021 at 5:00 p.m. (EDT) to discuss
financial results and corporate developments for the first quarter
ended March 31, 2021.
Jed Latkin, Chief Executive Officer, Dr. Michael Rosol, Chief
Medical Officer, and Joel Kaufman, Chief Business Officer, will
host the call and webcast to discuss the financial results and
provide an update on recent developments and clinical progress.
Management will be available to answer questions live immediately
following the earnings announcement and prepared remarks portion of
the call.
To participate in the call and webcast, please refer to the
information below:
Event: Q1 2021 Earnings and Business
Update Conference Call Date: Tuesday, May 11, 2021 Time:
5:00 p.m. (EDT) U.S. & Canada Dial-in: 877-407-0312
International Dial-in: +1 201-389-0899 Conference ID: 13718969
Webcast Link: https://www.webcast-eqs.com/navidbioph20210511/en
A live audio webcast of the conference call will also be
available on the investor relations page of Navidea’s corporate
website at www.navidea.com. In addition, the recorded conference
call can be replayed and will be available for 90 days following
the call on Navidea’s website.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is
developing multiple precision-targeted products based on its
Manocept™ platform to enhance patient care by identifying the sites
and pathways of disease and enable better diagnostic accuracy,
clinical decision-making, and targeted treatment. Navidea’s
Manocept platform is predicated on the ability to specifically
target the CD206 mannose receptor expressed on activated
macrophages. The Manocept platform serves as the molecular backbone
of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. Navidea’s strategy
is to deliver superior growth and shareholder return by bringing to
market novel products and advancing the Company’s pipeline through
global partnering and commercialization efforts. For more
information, please visit www.navidea.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. We have based these forward-looking statements largely on
our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
You are cautioned not to place undue reliance on any
forward-looking statements, any of which could turn out to be
incorrect. We undertake no obligation to update publicly or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise after the date of this
press release. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this press
release may not occur and actual results could differ materially
from those anticipated or implied in the forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210504005062/en/
Navidea Biopharmaceuticals, Inc. Jed Latkin Chief Executive
Officer 614-973-7490 jlatkin@navidea.com Joel Kaufman Chief
Business Officer 614-822-2372 jkaufman@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Apr 2023 to Apr 2024